NYSE:CTST - CannTrust Stock Price, Forecast & News

CannTrust's stock was trading at C$0.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTST shares have increased by 25.8% and is now trading at C$0.64. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CannTrust in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for CannTrust.

CannTrust is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for CannTrust.

8 Wall Street analysts have issued 12 month target prices for CannTrust's stock. Their forecasts range from C$2.00 to C$7.00. On average, they expect CannTrust's share price to reach C$4.50 in the next year. This suggests a possible upside of 605.3% from the stock's current price. View analysts' price targets for CannTrust.

Media stories about CTST stock have trended very negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CannTrust earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutCannTrust.

CannTrust saw a decrease in short interest in March. As of March 13th, there was short interest totaling 13,817,700 shares, a decrease of 5.2% from the February 27th total of 14,570,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is currently 8.4 days. Approximately 12.2% of the shares of the stock are sold short. View CannTrust's Current Options Chain.

Some companies that are related to CannTrust include Catalyst Pharmaceuticals (CPRX), CytomX Therapeutics (CTMX), BioDelivery Sciences International (BDSI), Ardelyx (ARDX), Corbus Pharmaceuticals (CRBP), Organogenesis (ORGO), Kala Pharmaceuticals (KALA), Merus (MRUS), Viking Therapeutics (VKTX), Wave Life Sciences (WVE), Beyondspring (BYSI), Mirum Pharmaceuticals (MIRM), OrganiGram (OGI), XBiotech (XBIT) and Dynavax Technologies (DVAX).

Based on aggregate information from My MarketBeat watchlists, some companies that other CannTrust investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Aphria (APHA), KushCo (KSHB), Cronos Group (CRON), Aurora Cannabis (ACB), OrganiGram (OGI), HEXO (HEXO), Nokia Oyj (NOK) and Aphria (APHA).

CannTrust trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTST."

Shares of CTST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CTST stock can currently be purchased for approximately C$0.64.

CannTrust has a market capitalization of C$90.27 million and generates C$35.22 million in revenue each year. The company earns C$-10,460,000.00 in net income (profit) each year or C($0.11) on an earnings per share basis. CannTrust employs 576 workers across the globe. View additional information about CannTrust.

The official website for CannTrust is http://www.canntrust.ca/.

CannTrust's mailing address is 3280 LANGSTAFF ROAD UNIT 1, VAUGHAN A6, L4K 4Z8. The company can be reached via phone at 64-7872-2300 or via email at [email protected]